Evaluating sustained adherence to ibrutinib in previously treated chronic lymphocytic leukaemia | Dr Jacqueline Barrientos at Annual Meeting 2015

Evaluating sustained adherence to ibrutinib in previously treated chronic lymphocytic leukaemia | Dr Jacqueline Barrientos at Annual Meeting 2015

EMJ

4 years
430 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the results of an analysis that evaluated the effect of a once-daily 420 mg dose of ibrutinib, a Bruton's tyrosine kinase inhibitor, on progression-free survival in patients with previously treated chronic lymphocytic leukaemia from the phase 3 RESONATE trial. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 45 minutes
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 46 minutes
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 46 minutes
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 46 minutes
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 46 minutes
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 47 minutes
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
1 Views
imedex 53 minutes
IASLC on Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection
IASLC on Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection
Category: Non-Small Cell Lung Cancer
10 Views
University of Torino 1 day
Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019
Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019
Category: News
19 Views
Cancer-News 1 day
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Category: Ovarian Cancer
22 Views
SeattleCCA 6 days